University of Abuja

Low-Dose Triple Combination Pill Shows Superior Blood Pressure Control in Landmark Trial

9 months ago

• A novel low-dose, three-in-one pill (GMRx2) significantly outperformed standard hypertension care in a Nigerian clinical trial. • The GMRx2 group achieved an 81% blood pressure control rate after one month, compared to 55% in the standard care group. • After six months, the GMRx2 group showed a 5.8 mmHg greater reduction in home systolic blood pressure compared to standard care. • George Medicines has submitted GMRx2 to the FDA for hypertension treatment, potentially impacting cardiovascular disease rates globally.